Work

A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps3103

Authors: Robert F. Cornell, Frederick Lundry Locke, Michael Russell Bishop, Robert Z. Orlowski, Sarah Marie Larson, Ivan Borrello, Sergio Giralt, Shaji Kumar, Ajay K. Nooka, Noopur S. Raje, John M. Rossi, Lisa Thomrongsith, Allen Xue, Zachary Roberts

Institutions: Vanderbilt University Medical Center, Moffitt Cancer Center, University of Chicago, The University of Texas MD Anderson Cancer Center, UCLA Medical Center, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Winship Cancer Institute, Massachusetts General Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892013826

Cites:

Cited by: 11

Related to: 10